MedGizmo - MedGizmo: Large Volume Wearable Injectors Update
19.02.2016, 09:33   MedGizmo

MedGizmo: Large Volume Wearable Injectors Update

Every patient knows that there is a need to visit medical facility in order to administer the drugs and medications. With the advent of new wearable technology, there is a new way to enhance patient care, reduce costs. New systems that allow patients to self-administer drugs are entering the market – and the terms 'Large volume Wearable Injectors’ is now in place. Another names that are used are ‘bolus injectors’ and ‘non-insulin patch pumps’. In this brief post, we provide some information and references that might help professionals and patients to evaluate existing and future possibilities; and select the right device that will improve your life.

First, some market insights.

Roots Analysis produced this Bolus Injectors Market, 2014 – 2024 Report  that states that the market is projected to generate $8 billion in device sales by 2024.
Some highlights:
  •  Approximately 67% of bolus injectors being developed operate electronically. Other modes of operation include mechanical, hydrogel and hydraulic. Many injectors have an audio / visual panel which facilitate the device usage by patients.
  • The range of these devices can cater to drug volume of as high as 30 ml, though majority of these devices are being designed to handle less than 5 ml of volume.
  • We anticipate the first commercial launch to take place in 2014/2015. There are a variety of biologics which are currently available for intravenous infusion delivery and are likely to be first targets for preparation of subcutaneous formulation and delivery via bolus injectors.
  •  Cancer will be the most researched area for bolus injectors. We expect cancer and related conditions to account for approx. 50% of the devices to be sold annually when the market matures. Other prominent target disease conditions are likely to be autoimmune diseases (approx. 11% share in 2024), blood disorders (approx. 7.9% share in 2024) and genetic disorders (approx. 7.8% share in 2024).
  • The growth in biologics will be one of the key drivers for the emergence of bolus injectors. According to our estimates, biologics are expected to be worth USD 215 billion by 2018, rising to USD 900 billion by 2024.
  • Other key reasons for the growth of bolus injectors include their potential to act as life cycle management tool, increasing trend towards drug self-administration and the overall drive towards cheaper healthcare costs.
Order Report HERE

The detailed report in the New York Times discusses the problems with injection of insulin, describes insulin pumps for the treatment of diabetes. It also cites a case where a single three-hour IV infusion of an auto-immune drug in a clinic generated a bill of $133,000. This, of course, shows the need for self-administered devices.
Read the full report HERE : Even Small Medical Advances Can Mean Big Jumps in Bills By ELISABETH ROSENTHAL

This special edition of OnDrugDelivery magazine is full of reference information on large volume injectors. Including interviews with representatives of major vendors. Highly recommend for reading

Major topics covered:
  • Introduction: Device Developer Perspective
  • Selecting the Right Wearable Injector Technology and Partner
  • A Large-Volume SC Delivery System Must Adjust to Drug & Patient Needs … not Vice Versa
  • Drug Packaging Systems for the Digital Health Era
  • Interviews: Getting to Know Enable Injections
  • Leveraging Patient-Centered Design to Deliver Large Volume Drugs

The magazine is complemented by this article:
Wearable Injectors Feature Article by Unilife CEO Alan Shortall in PMPS

One of the most recent developments in the field is associated with development of a Bioartificial Kidney.
Bioartificial kidneys using renal tubule cells and wearable dialysis are promising – they are to cover these unmet medical needs: acute renal failure, end stage renal disease, self-withdrawal from dialysis.

At the end of 2015 clinical trials of the wearable artificial kidney were conducted in Seattle. Seven patients wore the tool-belt-like device to cleanse their blood for 24 hours in a hospital.
The trial was successful and proved that the concept is workable. However, this faces some obstacles in development that are listed in this blog post: Wearable Artificial Kidney – Some Thoughts
Picture Source

One of the biggest players in the market is Unilife, Read this article by Alan Shortall, Chairman and CEO of Unilife.
Wearable Injectors: A Small Device That Can Make a Big Difference for IV Infusion

Today, there are more than 1,500 infusion pharmacy centers across the U.S. serving patients requiring IV administration of drugs in the home environment. The industry for home infusion care is estimated to generate $9 billion to $11 billion a year. Cost components for the home infusion market include the drug, bulky infusion equipment such as pumps, and a trained nurse or educator. Infusion pumps typically cost thousands of dollars to purchase, and according to government reports can cost patients between $30 and $75 per day to rent. Even compared to a hospital or clinic, these additional costs to patients and payors to have a drug administered via IV infusion in the home environment can be significant.
In response to this unmet need in the market, Unilife has developed a platform technology for the wearable injector market (also known as bolus injectors or patch pumps) for the subcutaneous injection of biologics and other drugs requiring large dose volumes or extended delivery periods
Precision-Therapy™ and Flex-Therapy™ wearable injectors can be optimized to control the duration, rate and volume of dose delivery. A safe, ergonomic and intuitive design provides a clear, comfortable and confident user experience during all stages of use.

Detailed presentation and information on Cell Therapy Devices in general and on wearable artificial kidney technology

This illustration by Improvements on Kidney Dialysis Treatment Alaa Ahmed, Dana Khawaja, Heba Al Johar, Roba Saab
The research paper Current status of bioartificial kidney by Sung Joon Shin provides comparison of various devices for wearable artificial kidney
Current status of bioartificial kidney, Sung Joon Shin

Extremely informative source is this Wearable & Implantable Renal Assist Devices
Porvides information and developments on  implantable renal assist device (iRAD);  Vicenza Wearable Artificial Kidney for Peritoneal Dialysis (ViWAK PD), peritoneal-based Automated Wearable Artificial Kidney, (AWAK); Wearable Artificial Kidney (WAK); Human Kidney Replacement Unit (HKRU);

Also, for those interested in Renal Assist Devices, here are two good links

Renal Fellow


19.02.2016, 09:33   MedGizmo
Image by MedGizmo
Views: 2040


When we provide links to other Web resources, the Company is not responsible for the accuracy, usefulness, safety, or intellectual property rights of or relating to such content.

Overview and Analysis

of information from Internet resources. Follow our Instagram Daily Feed @MedGizmo, Twitter Daily Feed @MedGizmo.
© 2016 MedGizmo